Campaign
AVeta Medical
MedTech
EIIS
AVeta has developed a technology to treat vaginal atrophy, a progressive and chronic condition that affects 80% of women over the age of 51.
€
1,200,000 Funding goal
€
1,392,893 Invested
198Investors
Company Summary :
AVeta is Galway-based. Its medical device is the only non-pharma hormone-free, safe, affordable, targeted therapy to treat vaginal symptoms of genitourinary syndrome of menopause (GSM), aka. vaginal atrophy (VA). It consists of a disposable, single-use intravaginal tip that is connected to a controller. The AVeta solution delivers a negative pressure treatment inducing an immune response to stimulate the natural healing process.
Key highlights:
- 80% of women globally over 51 yrs of age are affected by VA discomfort.
- US market alone worth $2 billion
- AVeta’s product uniquely delivers a hormone-free, safe, affordable and targeted therapy.
- Company has filed for patent protection.
- European EIC grant funding secured in 2021
- Early in-human trials demonstrate patient relief for 80% of trialists.
- AVeta team has impressive mix of experience in medical device development, completing clinical trials and working with regulatory bodies like the FDA, TUV and NSAI.